[1] Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol, 2010; 7, 515−25. doi:  10.1038/nrgastro.2010.116
[2] Rudler M, Weiss N, Bouzbib C, et al. Diagnosis and management of hepatic encephalopathy. Clin Liver Dis, 2021; 25, 393−417. doi:  10.1016/j.cld.2021.01.008
[3] Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver. Hepatology, 2014; 60, 715−35.
[4] Elsaid MI, Rustgi VK. Epidemiology of hepatic encephalopathy. Clin Liver Dis, 2020; 24, 157−74. doi:  10.1016/j.cld.2020.01.001
[5] Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol, 2015; 62, 437−47. doi:  10.1016/j.jhep.2014.09.005
[6] Berend K, Van Hulsteijn LH, Gans ROB. Chloride: the queen of electrolytes?. Eur J Intern Med, 2012; 23, 203−11. doi:  10.1016/j.ejim.2011.11.013
[7] Neyra JA, Canepa-Escaro F, Li XL, et al. Association of hyperchloremia with hospital mortality in critically ill septic patients. Crit Care Med, 2015; 43, 1938−44. doi:  10.1097/CCM.0000000000001161
[8] Suetrong B, Pisitsak C, Boyd JH, et al. Hyperchloremia and moderate increase in serum chloride are associated with acute kidney injury in severe sepsis and septic shock patients. Crit Care, 2016; 20, 315. doi:  10.1186/s13054-016-1499-7
[9] McCallum L, Jeemon P, Hastie CE, et al. Serum chloride is an independent predictor of mortality in hypertensive patients. Hypertension, 2013; 62, 836−43. doi:  10.1161/HYPERTENSIONAHA.113.01793
[10] Prins KW, Kalra R, Rose L, et al. Hypochloremia is a noninvasive predictor of mortality in pulmonary arterial hypertension. J Am Heart Assoc, 2020; 9, e015221. doi:  10.1161/JAHA.119.015221
[11] Li RG, Chen YX, Liang QH, et al. Lower serum chloride concentrations are associated with an increased risk of death in ICU patients with acute kidney injury: an analysis of the MIMIC-IV database. Minerva Anestesiol, 2023; 89, 166−74.
[12] Cuthbert JJ, Bhandari S, Clark AL. Hypochloraemia in patients with heart failure: causes and consequences. Cardiol Ther, 2020; 9, 333−47. doi:  10.1007/s40119-020-00194-3
[13] Cuthbert JJ, Pellicori P, Rigby A, et al. Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance. Eur J Heart Fail, 2018; 20, 1426−35. doi:  10.1002/ejhf.1247
[14] Johnson AEW, Bulgarelli L, Shen L, et al. MIMIC-IV, a freely accessible electronic health record dataset. Sci Data, 2023; 10, 1. doi:  10.1038/s41597-022-01899-x
[15] Chen C, Zhu AH, Ye SK, et al. A new dyslipidemia-based scoring model to predict transplant-free survival in patients with hepatitis E-triggered acute-on-chronic liver failure. Lipids Health Dis, 2023; 22, 80. doi:  10.1186/s12944-023-01826-y
[16] Hu XP, Gao J. International normalized ratio and model for end-stage liver disease score predict short-term outcome in cirrhotic patients after the resolution of hepatic encephalopathy. World J Gastroenterol, 2019; 25, 3426−37. doi:  10.3748/wjg.v25.i26.3426
[17] Riggio O, Celsa C, Calvaruso V, et al. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study. Front Med, 2023; 10, 1184860. doi:  10.3389/fmed.2023.1184860
[18] Gallego-Durán R, Hadjihambi A, Ampuero J, et al. Ammonia-induced stress response in liver disease progression and hepatic encephalopathy. Nat Rev Gastroenterol Hepatol, 2024; 21, 774−91. doi:  10.1038/s41575-024-00970-9
[19] Geng C, Xue Y, Yang JH, et al. SIRT1 mediates sestrin1-induced improvement in hepatic insulin resistance. Biomed Environ Sci, 2022; 35, 79−83.
[20] Häussinger D, Dhiman RK, Felipo V, et al. Hepatic encephalopathy. Nat Rev Dis Primers, 2022; 8, 43. doi:  10.1038/s41572-022-00366-6
[21] Doyon N, Vinay L, Prescott SA, et al. Chloride regulation: a dynamic equilibrium crucial for synaptic inhibition. Neuron, 2016; 89, 1157−72. doi:  10.1016/j.neuron.2016.02.030
[22] Wang ZY, Choi K. Pharmacological modulation of chloride channels as a therapeutic strategy for neurological disorders. Front Physiol, 2023; 14, 1122444. doi:  10.3389/fphys.2023.1122444
[23] De Koninck Y. Altered chloride homeostasis in neurological disorders: a new target. Curr Opin Pharmacol, 2007; 7, 93−9. doi:  10.1016/j.coph.2006.11.005
[24] Ditch KL, Flahive JM, West AM, et al. Hyperchloremia, not concomitant hypernatremia, independently predicts early mortality in critically ill moderate-severe traumatic brain injury patients. Neurocrit Care, 2020; 33, 533−41. doi:  10.1007/s12028-020-00928-0
[25] Huang KB, Hu YH, Wu YM, et al. Hyperchloremia is associated with poorer outcome in critically ill stroke patients. Front Neurol, 2018; 9, 485. doi:  10.3389/fneur.2018.00485
[26] Bei HZ, You SJ, Zheng D, et al. Prognostic role of hypochloremia in acute ischemic stroke patients. Acta Neurol Scand, 2017; 136, 672−9. doi:  10.1111/ane.12785
[27] Rodríguez-Triviño CY, Castro IT, Dueñas Z. Hypochloremia in patients with severe traumatic brain injury: a possible risk factor for increased mortality. World Neurosurg, 2019; 124, e783−8. doi:  10.1016/j.wneu.2019.01.025
[28] Sumarsono A, Wang JX, Xie LY, et al. Prognostic value of hypochloremia in critically ill patients with decompensated cirrhosis. Crit Care Med, 2020; 48, e1054−61. doi:  10.1097/CCM.0000000000004620
[29] Ji Y, Li LB. Lower serum chloride concentrations are associated with increased risk of mortality in critically ill cirrhotic patients: an analysis of the MIMIC-III database. BMC Gastroenterol, 2021; 21, 200. doi:  10.1186/s12876-021-01797-3
[30] Semmler G, Scheiner B, Balcar L, et al. Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis. Aliment Pharm Ther, 2023; 58, 71−9. doi:  10.1111/apt.17507
[31] Eliakim R, Shouval D, Eliakim M. Pathophysiological changes associated with increasing grade of hepatic encephalopathy. J Natl Med Assoc, 1988; 80, 986−91.
[32] Iwasa M, Sugimoto R, Mifuji-Moroka R, et al. Factors contributing to the development of overt encephalopathy in liver cirrhosis patients. Metab Brain Dis, 2016; 31, 1151−6. doi:  10.1007/s11011-016-9862-6
[33] Wunsch E, Naprawa G, Koziarska D, et al. Serum natremia affects health-related quality of life in patients with liver cirrhosis: a prospective, single centre study. Ann Hepatol, 2013; 12, 448−55.
[34] Jiang R, Tang J, Zhang X, et al. CCN1 Promotes inflammation by inducing IL-6 Production viaα6β1/PI3K/Akt/NF-κB pathway in autoimmune hepatitis. Front Immunol, 2022; 13, 810671. doi:  10.3389/fimmu.2022.810671